AZN•benzinga•
Reported Saturday, Daiichi Sankyo And AstraZeneca's ENHERTU Demonstrates 14.7-Month Median OS And 30% Reduction In Risk Of Death In HER2+ Gastric Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga